|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
EP0436597B1
(en)
|
1988-09-02 |
1997-04-02 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
|
DK0580737T3
(da)
|
1991-04-10 |
2004-11-01 |
Scripps Research Inst |
Heterodimere receptorbiblioteker ved anvendelse af phagemider
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
DK0690873T3
(da)
*
|
1993-03-19 |
2003-09-29 |
Univ Johns Hopkins Med |
Vækstdifferentieringsfaktor-8
|
|
US5994618A
(en)
*
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
US7566768B1
(en)
*
|
1995-10-26 |
2009-07-28 |
The Johns Hopkins University School Of Medicine |
Promyostatin peptides and methods of using same
|
|
US7393682B1
(en)
*
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
CA2194660C
(en)
|
1994-07-08 |
2009-09-29 |
Se-Jin Lee |
Growth differentiation factor-11
|
|
US20030167492A1
(en)
|
1994-07-08 |
2003-09-04 |
Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
|
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
EP1158997A2
(en)
|
1999-03-09 |
2001-12-05 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
|
BR0107902A
(pt)
|
2000-01-28 |
2002-11-05 |
Novo Nordisk As |
Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
AU2011244851A1
(en)
|
2000-07-27 |
2011-11-24 |
The John Hopkins University School Of Medicine |
Promyostatin peptides and methods of using same
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US8455627B2
(en)
|
2001-10-05 |
2013-06-04 |
Affimed Therapeutics, Ag |
Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
|
|
DE60128914T2
(de)
|
2001-10-05 |
2008-05-08 |
Affimed Therapeutics Ag |
Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
|
|
US20040219142A1
(en)
|
2002-07-19 |
2004-11-04 |
Abbott Laboratories S.A. |
Treatment of skin and nail disorders using TNFalpha inhibitors
|
|
EP2192129A1
(en)
|
2002-09-16 |
2010-06-02 |
Johns Hopkins University |
Metalloprotease activation of myostatin, and methods of modulating myostatin activity
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
DE60333228D1
(de)
|
2002-12-02 |
2010-08-12 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
|
CN101287484B
(zh)
|
2002-12-20 |
2012-10-10 |
安姆根有限公司 |
抑制肌肉生长抑制素的结合剂
|
|
CA2551877A1
(en)
|
2003-12-31 |
2005-07-21 |
Schering-Plough Ltd. |
Neutralizing epitope-based growth enhancing vaccine
|
|
EP1729793B1
(en)
|
2004-03-02 |
2015-07-22 |
Acceleron Pharma Inc. |
Alk7 and myostatin inhibitors for muscle wasting disorders
|
|
ATE557042T1
(de)
|
2004-03-23 |
2012-05-15 |
Lilly Co Eli |
Anti-myostatin-antikörper
|
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
AU2005247508A1
(en)
|
2004-05-27 |
2005-12-08 |
Acceleron Pharma Inc. |
Cerberus/coco derivatives and uses thereof
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
|
US20060216279A1
(en)
|
2005-03-22 |
2006-09-28 |
Glass David J |
Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
|
|
NL1031674C2
(nl)
|
2005-04-25 |
2007-04-26 |
Pfizer |
Antilichamen tegen myostatine.
|
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
|
BRPI0616923A2
(pt)
|
2005-10-06 |
2011-07-05 |
Lilly Co Eli |
anticorpos monoclonais, seus usos e composição farmacêutica
|
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
WO2007061995A2
(en)
|
2005-11-21 |
2007-05-31 |
Novartis Ag |
Biomarkers for statin-induced myopathy or rhabdomyolysis
|
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
US8309068B2
(en)
|
2006-08-03 |
2012-11-13 |
Myostin Therapeutics Pty Ltd. |
Isolated polypeptides and methods of improving muscle strength
|
|
CA2661836A1
(en)
|
2006-09-05 |
2008-03-13 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
CA2693178C
(en)
|
2006-11-29 |
2018-12-04 |
Nationwide Children's Hospital, Inc. |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
|
WO2008103471A2
(en)
|
2007-02-23 |
2008-08-28 |
The Trustees Of Columbia University In The City Of New York |
Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
|
|
EP2129742B1
(en)
|
2007-03-30 |
2012-01-25 |
Merck Patent GmbH |
Birefingent layer with negative optical dispersion
|
|
AU2008260445A1
(en)
|
2007-06-01 |
2008-12-11 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
|
EP2401293B1
(en)
|
2009-02-24 |
2016-02-10 |
The Salk Institute For Biological Studies |
Designer ligands of tgf-beta superfamily
|
|
JP5766179B2
(ja)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
筋肉増殖を増加させるための組成物および方法
|
|
BRPI1010587A2
(pt)
|
2009-06-08 |
2019-04-09 |
Acceleron Pharma Inc. |
métodos para aumentar adipócitos termogênicos
|
|
US8945511B2
(en)
|
2009-06-25 |
2015-02-03 |
Paul Weinberger |
Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
|
|
CN102741276A
(zh)
|
2009-10-01 |
2012-10-17 |
可维塔有限公司 |
合成的肌肉抑制素肽拮抗剂
|
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
|
US8999343B2
(en)
|
2010-08-16 |
2015-04-07 |
Amgen Inc. |
Antibodies that bind myostatin, compositions and methods
|
|
CA2852127C
(en)
|
2011-11-11 |
2020-10-27 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
AU2012339722B2
(en)
|
2011-11-14 |
2017-09-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
|
|
US20130178454A1
(en)
|
2011-11-17 |
2013-07-11 |
Shalender Bhasin |
Combination of testosterone and ornithine decarboxylase (odc) inhibitors
|
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
|
WO2013165972A2
(en)
|
2012-04-30 |
2013-11-07 |
Cell Signaling Technology, Inc. |
Anti-hepatitis b virus antibodies and use thereof
|
|
EP2861617A1
(en)
*
|
2012-06-15 |
2015-04-22 |
Pfizer Inc. |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
US20150284455A1
(en)
|
2012-11-06 |
2015-10-08 |
Scholar Rock, Inc. |
Compositions and methods for modulating cell signaling
|
|
HRP20251426T1
(hr)
*
|
2013-05-06 |
2026-01-02 |
Scholar Rock, Inc. |
Sastavi i postupci za modulaciju faktora rasta
|
|
EP2853898B1
(en)
|
2013-09-27 |
2017-01-04 |
Medizinische Hochschule Hannover |
Analysis of myostatin in serum
|
|
US10004814B2
(en)
*
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
WO2015195094A1
(en)
|
2014-06-17 |
2015-12-23 |
Ember Therapeutics, Inc. |
Anti-activin and nati-myostatin antibodies and methods of using the same
|
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
|
HK1243940A1
(zh)
|
2014-11-06 |
2018-07-27 |
Scholar Rock, Inc. |
抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
WO2016168613A1
(en)
|
2015-04-15 |
2016-10-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of increasing strength and functionality with gdf8 inhibitors
|
|
LT3350220T
(lt)
|
2015-09-15 |
2021-09-27 |
Scholar Rock, Inc. |
Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
|
|
CN115814077A
(zh)
|
2016-01-08 |
2023-03-21 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
|
|
AU2017283546C1
(en)
|
2016-06-13 |
2020-11-19 |
Scholar Rock, Inc. |
Use of myostatin inhibitors and combination therapies
|
|
JOP20190152A1
(ar)
|
2016-12-21 |
2019-06-20 |
Novartis Ag |
مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
|
|
ES2944357T3
(es)
|
2017-01-06 |
2023-06-20 |
Scholar Rock Inc |
Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
|